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Abstract
Aims/hypothesis This study aimed to examine the relation-
ship between average glucose levels, assessed by continu-
ous glucose monitoring (CGM), and HbA1c levels in preg-
nant women with diabetes to determine whether calcula-
tions of standard estimated average glucose (eAG) levels
from HbA1c measurements are applicable to pregnant
women with diabetes.
Methods CGM data from 117 pregnant women (89 wom-
en with type 1 diabetes; 28 women with type 2 diabetes)
were analysed. Average glucose levels were calculated
from 5–7 day CGM profiles (mean 1275 glucose values
per profile) and paired with a corresponding (±1 week)
HbA1c measure. In total, 688 average glucose–HbA1c pairs
were obtained across pregnancy (mean six pairs per par-
ticipant). Average glucose level was used as the dependent
variable in a regression model. Covariates were gestational
week, study centre and HbA1c.
Results There was a strong association between HbA1c and
average glucose values in pregnancy (coefficient 0.67 [95%
CI 0.57, 0.78]), i.e. a 1% (11 mmol/mol) difference in HbA1c
corresponded to a 0.67 mmol/l difference in average glucose.
The random effects model that included gestational week as a
curvilinear (quadratic) covariate fitted best, allowing calcula-
tion of a pregnancy-specific eAG (PeAG). This showed that an
HbA1c of 8.0% (64mmol/mol) gave a PeAG of 7.4–7.7mmol/l
(depending on gestational week), compared with a standard
eAG of 10.2 mmol/l. The PeAG associated with maintaining
an HbA1c level of 6.0% (42 mmol/mol) during pregnancy was
between 6.4 and 6.7 mmol/l, depending on gestational week.
Conclusions/interpretation The HbA1c–average glucose re-
lationship is altered by pregnancy. Routinely generated
standard eAG values do not account for this difference
between pregnant and non-pregnant individuals and, thus,
should not be used during pregnancy. Instead, the PeAG
values deduced in the current study are recommended for
antenatal clinical care.
Keywords Average glucose . Continuous glucose
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Pregnant . Type 1 diabetes . Type 2 diabetes
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Introduction
The relationship between HbA1c and average glucose
levels has been explored in many studies, most making
use of intermittent capillary blood glucose measurements
[1–6]. More recently, intensive longitudinal data from
continuous glucose monitoring (CGM) have been used
to derive a more accurate picture of how average glucose
levels compare with HbA1c over time [7–11]. The A1C-
Derived Average Glucose (ADAG) study showed a linear
association between CGM-measured average glucose and
HbA1c levels in non-pregnant adults with type 1 and type
2 diabetes [8]. Following endorsement of the ADAG
analysis by the ADA, EASD, International Diabetes
Federation (IDF) and International Federation of
Clinical Chemists (IFCC) [12], many laboratories now
report HbA1c data as a standard estimated average glu-
cose (eAG) alongside the HbA1c result, facilitating great-
er patient understanding of how daily glucose measure-
ments relate to HbA1c levels.
The ability to accurately assess glucose control is crit-
ical in the context of pregnancy in women with diabetes,
where achieving tight glucose control has a beneficial im-
pact on maternal–fetal health outcomes. However, HbA1c
is considered unreliable for assessing glucose control dur-
ing pregnancy owing to physiological changes that may be
attributed to increased red cell production, shortened red
cell life span, reduced red cell affinity for glucose, iron
deficiency and iron supplementation [13–17]. This has led
to uncertainty over the role of HbA1c for blood glucose
assessment in pregnancy [18], with key bodies [19, 20]
advising that it should not be used for diagnosing diabetes
in pregnancy, and the National Institute for Health and
Care Excellence (NICE) in the UK recommending that it
should not be routinely used to assess glucose control in
pregnancy in women with established diabetes [20].
Furthermore, the relationship between any physiological
changes in HbA1c across pregnancy and average glucose
levels obtained by CGM is unknown. Despite these limi-
tations, HbA1c is widely used in clinical practice during
pregnancy in the UK [21], the USA [22] and internation-
ally [23]. Anecdotal reports also suggest that clinicians
and patients are using the standard eAG value, which is
reported with HbA1c levels, during pregnancy, despite it
being derived from data from non-pregnant adults.
Thus, the aims of this analysis were to: (1) examine the
relationship between average glucose levels assessed by
CGM and HbA1c levels in pregnancy in women with type
1 and type 2 diabetes; (2) determine if this relationship
changes with gestational week during pregnancy; and (3)
determine whether the standard eAG calculation that is
derived from HbA1c measurements is applicable to preg-
nant women with diabetes.
Methods
Participants This analysis used data obtained from two pre-
viously published studies: one based in the UK (East Anglia)
[24] and the second in Denmark (Copenhagen) [25]. Both
studies recruited pregnant women with pregestational type 1
or type 2 diabetes to prospective randomised controlled trials
that explored the clinical impact of CGM on maternal, fetal
and neonatal health outcomes. In the UK, pregnant partici-
pants, aged 16–45 years, were recruited from two secondary
care diabetes antenatal clinics between 2003 and 2006. In
Denmark, pregnant participants, aged 19–43 years, were re-
cruited from one diabetes antenatal clinic between 2009 and
2011. Full details of clinical recruitment procedures (including
the exclusion of participants with severe medical or psycho-
logical comorbidities) have been described previously
[24–26]. A total of 117 participants (49 from England and
68 from Denmark), comprising 89 women with type 1 diabe-
tes and 28 with type 2 diabetes, were included in the present
analysis [26].
All participants gave written informed consent. Ethical ap-
proval was granted by the Suffolk and Norfolk Local
Research Ethics Committee and the Danish National
Committee on Biomedical Research Ethics. The Helsinki
Declaration and Good Clinical Practice guidelines were ad-
hered to throughout the study.
Antenatal and perinatal care All participants received routine
clinical care as per national guidelines. In the UK, this involved
antenatal clinic visits every 2–4 weeks, with 4–6 visits including
CGM and HbA1c measurements. In Denmark, antenatal clinic
visits occurred every 2 weeks, with five study visits at 8, 12,
21, 27 and 33 weeks gestation. These study visits included
CGM and HbA1c measurements. CGM profiles were collected
over 5–7 days. Both studies used comparable glucose targets to
achieve optimum glucose control; in the UK, these were:
<5.5 mmol/l before meals, <7.8 mmol/l at 60 min postprandial
and <6.7 mmol/l at 120 min postprandial. In Denmark, glucose
targets were set at 4.0–6.0 mmol/l before meals, 4.0–8.0 mmol/l
at 90 min postprandial and 6.0–8.0 mmol/l before bed.
CGM Continuous glucose monitors were used to record elec-
trochemically measured subcutaneous interstitial glucose con-
centrations every 5 min, generating 288 measurements per
day. Both studies used Medtronic CGM systems (MiniMed,
Medtronic, Northridge, CA, USA), with CGM Gold sensors
being used in the UK and Guardian REAL-Time CGM with
Sof-sensors being used in Denmark. Monitors were calibrated
against capillary blood glucose measurements as per the man-
ufacturer’s instructions.
HbA1c Blood samples for HbA1c measurements were obtain-
ed regularly throughout pregnancy at both centres. Samples
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were analysed locally by assays that were DCCT-aligned and
from laboratories with National Glycohemoglobin
Standardization Program (NGSP) certification.
Statistical analysis Average glucose was calculated as the
mean of all glucose values obtained in the 5–7 day CGM
profile. The corresponding week of gestation was noted for
glucose values and, for analysis, values were paired with the
HbA1c values that had been measured within ± 1 week of the
CGM profile. Each calculated average glucose value was
matched to an individual HbA1c, though women contributed
multiple average glucose–HbA1c pairs across their pregnancy.
A mixed-effects regression model was therefore used to ac-
count for the intra-individual variation with multiple data pairs
per woman. In seeking the best-fitting model for the relation-
ship between average glucose and HbA1c, this model included
the covariates: gestational age in weeks, HbA1c level and
study centre (all centred to their grand mean). The models
were explored for linear and curvilinear (squared) relation-
ships, with model fit being assessed using the Akaike infor-
mation criterion [27], whereby a lower score indicated a better
fit of the model. All analyses were conducted in Stata 13,
version 13 (StataCorp, College Station, TX, USA).
Results
Relationship between average glucose levels and HbA1c in
pregnancy A total of 688 CGM profiles with a mean of 1275
(range 313–2839) glucose measures per profile were obtained
for comparison with 688 HbA1c levels. Each woman contrib-
uted an average of six average glucose–HbA1c pairs across
their pregnancy, at between 8 and 36 weeks gestation.
Fig. 1 shows the association between average glucose and
HbA1c values obtained during pregnancy. A linear regression
line, with 95% CI, is fitted to the data points (r2 = 19.6%;
average glucose–HbA1c slope=0.67 [0.57, 0.78]), showing a
strong positive association. This implies that, for these
women, on average a 1% (11 mmol/mol) difference in
HbA1c corresponded to a 0.67 mmol/l difference in their
average glucose levels.
Determining the best-fitting model to account for how ges-
tational changes in HbA1c influence the average glucose–
HbA1c relationship An intercept-only mixed-effects model
was compared with models containing random effects for
the slope of the average glucose values in relation to HbA1c
levels (Table 1 and electronic supplementary material [ESM]
Table 1). As the model containing the random effects of the
slope coefficient provided a significant improvement in fit, the
random slope was retained. The best-fitting model, with the
lowest Akaike information criterion score, was model 5 (see
Table 1). This model fitted average glucose to HbA1c, study
centre, gestation in weeks (linear) and gestation in weeks
squared (curved). Model 6 examined an interaction between
HbA1c and gestation in weeks to determine whether the gra-
dient between average glucose and HbA1c changed during
pregnancy; the findings showed that it did not. There was also
no interaction between HbA1c and study centre, demonstrat-
ing that the relationship between average glucose and HbA1c
was consistent across the two datasets.
Deriving a pregnancy-specific eAG Using the best-fitting
curvilinear model, Fig. 2 shows the study mean pregnancy-
specific eAG (PeAG) levels changing with gestational week
for a range of HbA1c levels. As an example, if the HbA1c is
measured at 6.0% (42 mmol/mol) during the 12th week of
gestation, the PeAG is 6.7 mmol/l, whereas if it is measured
at 36 weeks gestation the PeAG is 6.4 mmol/l. To estimate
PeAG at any given week during pregnancy, the following
equation can be used:
Glucose mmol=lð Þ ¼ 6:78 þ 0:43 HbA1c %½  − 6:3ð Þ½ 
þ 0:04 Gestation weeks½  − 21ð Þ½ 
− ½0:001 ðGestation weeks½ 2 − 528Þ
Comparison of PeAGwith the ADAG-calculated eAG The
eAG derived using the ADAG formula and that derived by our
pregnancy-specific equation for a given value of HbA1c are
shown in Table 2. If we were to use the ADAG formula, an
HbA1c of 6.0% (42 mmol/mol) would equate to an eAG of
7 mmol/l irrespective of the gestational week, whereas it
would equate to a lower PeAG (between 6.4 and 6.7 mmol/l
depending on gestational week) using our pregnancy-specific
equation. This difference is more pronounced at higher levels
of HbA1c, where an HbA1c of 8.0% (64 mmol/mol) equates to
a PeAG of 7.7 mmol/l (at 12 weeks gestation and a PeAG of
7.4 mmol/l at 36 weeks gestation but, in contrast, using the
ADAG formula, the same HbA1c value would equate to an
eAG of 10.2 mmol/l throughout gestation [8].
Discussion
This is the first study to examine the relationship between
average glucose levels obtained by CGM and HbA1c levels
during pregnancy in women with diabetes. Our analysis dem-
onstrates a positive linear relationship between average glu-
cose and HbA1c levels, but the slope is shallower than that
reported in non-pregnant adults [8]. This validates the use of
HbA1c to represent average glucose levels during pregnancy,
but suggests that a change in HbA1c during pregnancy reflects
a smaller change in average glucose than that assumed using
the ADAG model [8, 12]. In addition, while we have shown
that the relationship between average glucose and HbA1c is
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stable during pregnancy, the absolute mean eAG varies with
gestational week. Consequently, HbA1c in pregnancy is asso-
ciated with a lower eAG than that calculated by ADAG and
this difference becomes more marked later in pregnancy. This
means that the standard eAG reported with HbA1c is not rep-
resentative of average glucose levels in pregnancy and should
not be used for assessing glucose control in pregnancy. We
provide an alternative pregnancy-specific calculation for
PeAG based on the observed relationship of HbA1c and aver-
age glucose during pregnancy.
The work of the ADAG team has embedded the translation
of eAG from HbA1c into routine clinical practice [8, 12].
However, the ADAG analysis deliberately excluded pregnant
women because of pregnancy-related physiological changes in
HbA1c [8] and, as a result, the routinely derived eAG may not
be applicable to this population. HbA1c is known to fall with
the physiological changes associated with pregnancy, particu-
larly in early and late pregnancy [13–17]. A strength of our
study is that average glucose and HbA1c data were obtained
on repeated occasions (a mean of six times) in the same woman
throughout pregnancy, enabling us to take account of gestation-
al week in our data analysis. This revealed the stability of the
average glucose–HbA1c relationship across pregnancy.
While our data confirm that a positive association exists
between average glucose and HbA1c, the slope of the relation-
ship was shallower than that seen in non-pregnant adults
Table 1 Comparison of an inter-
cept-only mixed-effects model
with models containing random
effects to determine the best-
fitting model to account for how
gestational changes in HbA1c in-
fluence the average glucose–
HbA1c relationship
Model AIC Fixed effects Intercept HbA1c Other covariates
1 1911.58 Intercept only 6.88 (6.70, 7.05)
2 1762.65 + HbA1c 6.84 (6.69, 7.00) 0.57 (0.37, 0.77)
3 1759.12 + HbA1c
+ Centre
6.79 (6.63, 6.95) 0.55 (0.35, 0.75) −0.39 (−0.70, −0.08)
4 1753.49 + HbA1c
+ Centre
+ Gestation
6.77 (6.61, 6.93) 0.43 (0.22, 0.64) −0.43 (−0.75, −0.12)
−0.01 (−0.02, −0.00)
5 1750.17 + HbA1c
+ Centre
+ Gestation
+ Gestation2
6.78 (6.62, 6.94) 0.50 (0.28, 0.72) −0.39 (−0.70, −0.07)
0.04 (−0.01, 0.08)
−0.001 (−0.002, −0.000)
6 1752.15 + HbA1c
+ Centre
+ Gestation
+ Gestation2
+ HbA1c × Gestation
6.78 (6.62, 6.94) 0.50 (0.28, 0.72) −0.39 (−0.70, −0.07)
0.03 (−0.01, 0.08)
−0.001 (−0.002, −0.000)
0.00 (−0.01, 0.02)
Data shown as regression coefficient (95% CI)
The mixed-effects models were fit between average glucose as the outcome and explanatory variables, using time
nested within each mother
AIC, Akaike information criterion
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Fig. 1 Average glucose against
HbA1c in diabetes. A graph
showing average glucose vs
HbA1c with a linear fit and 95%
CI. White circles, women with
type 1 diabetes; black circles,
women with type 2 diabetes. To
convert values for HbA1c in %
into mmol/mol, subtract 2.15 and
multiply by 10.929
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[7–9], and this gradient remained stable during the last two
trimesters of pregnancy. For example, previous data indicate
that a 1% (11 mmol/mol) difference in HbA1c is equivalent to
a 1.0–2.0 mmol/l difference in average glucose [7–9, 11],
whereas our data show that in pregnancy a much smaller dif-
ference in average glucose, 0.67 mmol/l, equates to a 1%
(11 mmol/mol) difference in HbA1c. This suggests that a
change in HbA1c during pregnancy reflects a smaller change
in average glucose compared with that seen outside of
pregnancy.
Having established that the gradient between the average
glucose–HbA1c relationship is stable from the first trimester in
pregnancy, there are nevertheless challenges when translating
HbA1c levels to eAG values, given the physiological changes
that occur in pregnancy. The implication of a fall in HbA1c or
average glucose levels as pregnancy progresses means that
any fluctuations in either become more sensitive to the gradi-
ent relationship. We have shown that gestational week is an
important factor to account for when calculating an eAG from
the average glucose–HbA1c relationship during pregnancy,
since mean levels of average glucose vary throughout preg-
nancy. Using our best-fitting model, the HbA1c during preg-
nancy translates to a PeAG that is of a magnitude of 0.5–
2.8 mmol/l difference compared with the eAG obtained using
the ADAG formula that laboratories report [8, 12], and this
difference is more pronounced at higher levels of HbA1c
(Table 2). This means that pregnant women and their
clinicians could be misled by the standard eAG readings cur-
rently generated for laboratory reports and by automated on-
line calculators. Furthermore, many glucose-monitoring de-
vices generate an estimated HbA1c from average glucose data.
It is likely that this HbA1c estimation is currently based on the
ADAG formula, which may also be unintentionally mislead-
ing during pregnancy.
We consider that our analysis performed in pregnant wom-
en builds substantially on the ADAG team’s work. It is im-
portant, however, to note that while there are similarities, there
are also several differences between our analysis and that of
the ADAG. In contrast to the prospectively designed ADAG
study [8], ours and other studies [9, 11] were pragmatic and
made use of existing clinical data obtained from other studies.
Compared with the ADAG study, which used 507 partici-
pants, of whom 427 had diabetes [8], our study is relatively
small and we recognise that a larger study would help to im-
prove the precision of our model to more confidently ascertain
the relationship between average glucose and HbA1c levels. In
addition, the ADAG study included participants with a greater
range of HbA1c levels, including many with far higher HbA1c
values than the participants in our study.
The ADAG study paired the average glucose measures
obtained by intermittent CGM readings taken for 2–3 days,
every 4 weeks over a period of 3 months (giving ∼2500 glu-
cose values per participant) to an HbA1c taken at the end of the
3 months measurement period [8], resulting in one average
glucose–HbA1c pair per participant. In contrast, to address
the complex issue of gestational physiological changes in
HbA1c, the average glucose values obtained in our study were
derived from an individual CGM session of 5–7 days, (giving
a mean of 1275 glucose values), and were compared with an
HbA1c value taken within ± 1 week of the CGM profile, yield-
ing a mean of six average glucose–HbA1c pairs per partici-
pant. Previous small studies conducted in the 1980s used cap-
illary blood glucose testing to calculate average glucose in
pregnancy and showed a strong positive correlation between
HbA1c and the preceding 8–12 weeks’ average glucose values
[28, 29]. We obtained the strongest relationship between
average glucose and HbA1c when both were measured within
a few weeks of each other (ESM Table 2), suggesting that in
pregnancy an HbA1c value is more reflective of current aver-
age glucose readings (obtained by CGM) than those obtained
Table 2 Comparison of eAG
values calculated from varying
levels of HbA1c using the ADAG
calculation, vs the PeAG
calculation.
HbA1c
% (mmol/mol)
ADAG eAG
mmol/l
PeAG mmol/l
12 weeks gestation 24 weeks gestation 36 weeks gestation
5.0 (31) 5.4 6.2 6.2 5.9
6.0 (42) 7.0 6.7 6.7 6.4
7.0 (53) 8.6 7.2 7.2 6.9
8.0 (64) 10.2 7.7 7.7 7.4
6.0
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8.0
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Fig. 2 Changes in PeAG during gestation calculated for a range of
HbA1c using the best-fitting model. Long dash, 5.0% (31 mmol/mol)
HbA1c; dash/dot, 6.0% (42 mmol/mol) HbA1c; solid line, 7.0%
(53 mmol/mol) HbA1c; short dash, 8.0% (64 mmol/mol) HbA1c
622 Diabetologia (2017) 60:618–624
over the preceding 3 months. Anecdotally, it is very common
to see dramatic reductions in HbA1c over very short periods of
time (<4 weeks) at the start of pregnancy as women are mo-
tivated to rapidly optimise their glucose control upon finding
out that they are pregnant; this may account for this more
proximal relationship.
The ADAG study chose to weight their analysis with inter-
mittent daytime capillary glucose readings but we did not. The
rationale for weighting their analysis is unclear as: (1) CGM is
already calibrated with regular capillary glucose readings; and
(2) intermittent capillary glucose readings do not represent the
‘true’ average glucose value across the 24 h day since they are
intermittent, ignore overnight glucose levels and may be skewed
by postprandial glucose excursions. Since the ADAG analysis
found that the average glucose–HbA1c relationship was un-
changed if only CGM readings were used for analysis, we de-
cided to adopt this approach and not weight our analysis [8].
Our data have some further limitations; the women in our
study were predominantly white European, which may limit
applicability of our findings to women from other cultures and
backgrounds. Our analysis did not include any women with
gestational diabetes, so care needs to be taken with regard to
its applicability in this context. We did not have data on
haematocrit levels or iron deficiency/supplementation in our
participants but, given that these are factors in the physiolog-
ical changes of HbA1c during pregnancy, this information
might be useful to include in any future analysis of HbA1c
and average glucose levels in pregnancy.
We know from population-based studies that HbA1c in
pregnancy is a useful guide for pregnancy outcome and risk
stratification [30] and is recommended by NICE for this pur-
pose [20]. The ADA recommends regular assessment of glu-
cose control during pregnancy, using monthly HbA1c, to
maintain a level of 6.0–6.5% (42–48 mmol/mol) [22]; how-
ever, NICE was unable to make this recommendation because
of a lack of data for validation of the relationship between
HbA1c to average glucose levels during pregnancy [20]. Our
current analysis now provides this validation.
CGM is increasingly being used in clinical practice. The
average glucose level calculated from the intensive longitudi-
nal glucose data on these devices is far superior to that obtain-
ed by capillary glucose meters. Increasing the accessibility
and use of CGM as an alternative to capillary glucose testing
may significantly improve glucose management during preg-
nancy [24–26]. One of the difficulties of using CGM in preg-
nancy is determining exactly which aspects of glucose control
to target. Targeting weekly PeAG could be a simple way to
help women achieve the glucose control necessary to maintain
their HbA1c at ‘low risk’ levels across pregnancy. Our data
would suggest that maintaining a PeAG of 6.4–6.7 mmol/l
throughout pregnancy should achieve an HbA1c of 6.0%
(42 mmol/mol), which is necessary for reducing the risk of
adverse pregnancy outcomes.
In summary, HbA1c can be translated to eAG values in
pregnant women with diabetes, but these are not the same as
those commonly reported. Therefore, pregnancy-specific
values, PeAG, are recommended for use in antenatal clinical
care.
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